文献速递肿瘤 PET/CT核素与放射性配体治疗

[68Ga]Ga-FAPI PET/CT与[18F]FDG PET/CT在胆道癌中诊断性能比较:系统评价与Meta分析

Comparative diagnostic performance of [68 Ga]Ga-FAPI PET/CT and [18 F]FDGPET/CT in biliary tract cancers: a systematic review and meta-analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-11

该系统评价与Meta分析检索截至2024年3月的多个数据库,直接比较[68Ga]Ga-FAPI与[18F]FDG PET/CT检测胆道癌。汇总OR为4.87(95%CI 1.75-13.56),肿瘤SUVmax平均差异6.47(95%CI 1.81-11.13),淋巴结转移OR 2.81(95%CI 1.07-7.35),远处转移OR 3.45(95%CI 1.12-10.63)。结论认为[68Ga]Ga-FAPI PET/CT诊断性能和肿瘤摄取优于[18F]FDG PET/CT。

要点

  • [68Ga]Ga-FAPI PET/CT检测胆道癌的汇总OR为4.87(95%CI 1.75-13.56),优于[18F]FDG PET/CT。
  • 肿瘤SUVmax平均差异6.47(95%CI 1.81-11.13),TBRmax平均差异9.45(95%CI 3.88-15.03)。
  • 淋巴结转移OR 2.81(95%CI 1.07-7.35),远处转移OR 3.45(95%CI 1.12-10.63)。

核心结论

  • [68Ga]Ga-FAPI PET/CT在胆道癌中诊断性能和肿瘤摄取优于[18F]FDG PET/CT,尤其在淋巴结和远处转移检测方面。
  • 这些发现支持[68Ga]Ga-FAPI PET/CT作为胆道癌首选成像方式的潜在临床效用,但需进一步研究以标准化方案并在更大队列中确认结果。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、EMBASE、Web of Science、Scopus和Cochrane Library截至2024年3月。
  • 纳入直接比较[68Ga]Ga-FAPI与[18F]FDG PET/CT检测胆道癌的研究。
  • 采用随机效应模型评估敏感性、特异性、肿瘤SUVmax和TBRmax的汇总平均差异及检测原发肿瘤、淋巴结和远处转移的比值比及95%置信区间。
  • 对肝内胆管癌(IHCC)进行亚组分析。

主要发现

  • [68Ga]Ga-FAPI PET/CT对比[18F]FDG PET/CT的汇总OR为4.87(95%CI 1.75-13.56,I²=0.0%,p=0.60),差异有统计学意义。
  • IHCC亚组汇总OR为2.98(95%CI 0.86-10.38,I²=0.0%,p=0.63),倾向于[68Ga]Ga-FAPI。
  • 胆道癌中[68Ga]Ga-FAPI肿瘤摄取显著高于[18F]FDG PET/CT,SUVmax汇总平均差异6.47(95%CI 1.81-11.13),TBRmax汇总平均差异9.45(95%CI 3.88-15.03)。
  • IHCC亚组TBRmax平均差异7.71(95%CI -0.58-16.01),未达统计学显著。
  • 淋巴结转移检测OR 2.81(95%CI 1.07-7.35),远处转移检测OR 3.45(95%CI 1.12-10.63);淋巴结和器官转移研究间存在中度异质性(I²分别为46.9%和52.4%)。

关键数值与推荐

  • 胆道癌中[68Ga]Ga-FAPI对比[18F]FDG PET/CT的汇总OR 4.87(95%CI 1.75-13.56)。
  • IHCC亚组汇总OR 2.98(95%CI 0.86-10.38)。
  • SUVmax汇总平均差异6.47(95%CI 1.81-11.13),TBRmax汇总平均差异9.45(95%CI 3.88-15.03)。
  • 淋巴结转移OR 2.81(95%CI 1.07-7.35),远处转移OR 3.45(95%CI 1.12-10.63)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 淋巴结转移和器官转移检测研究间存在中度异质性(I²分别为46.9%和52.4%)。
  • 需进一步研究以标准化方案并在更大队列中确认结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biliary tract cancers (BTCs) are aggressive malignancies with poor prognosis due to late-stage diagnosis. While [18 F]-FDG PET/CT is widely used for detection and staging, its sensitivity for certain BTC subtypes is limited, prompting the evaluation of 68 Ga-FAPI PET/CT as a promising alternative. OBJECTIVE: To compare the diagnostic performance of [68 Ga]Ga-FAPI PET/CT and [18 F]FDG PET/CT in detecting BTCs, including primary tumors, lymph node involvement, and distant metastases. METHODS: We searched PubMed, EMBASE, Web of Science, Scopus, and the Cochrane Library until March 2024 to identify studies that directly compared [68 Ga]Ga-FAPI and [18 F]FDG PET/CT in detecting BTCs. Sensitivity, specificity, pooled mean differences of tumor SUVmax and TBRmax, and odds ratios for detecting primary tumors, lymph nodes, and distant metastases using a random-effects model with the corresponding 95% confidence intervals were evaluated. Subgroup analyses were performed for intrahepatic cholangiocarcinoma (IHCC). RESULTS: The pooled OR for [68 Ga]Ga-FAPI PET/CT versus [18 F]FDG PET/CT was 4.87 (95% CI: 1.75-13.56, I2 = 0.0%, p = 0.60), indicating a statistically significant preference for [68 Ga]Ga-FAPI. In the IHCC subgroup, the pooled OR was 2.98 (95% CI: 0.86-10.38, I2 = 0.0%, p = 0.63) favors [68 Ga]Ga-FAPI. Furthermore, [68 Ga]Ga-FAPI demonstrated significantly higher tumor uptake compared to [18 F]FDG PET/CT, with pooled mean differences in SUVmax of 6.47 (95% CI: 1.81-11.13) and TBRmax of 9.45 (95% CI: 3.88-15.03) across BTCs. Subgroup analysis for IHCC showed a trend favoring [68 Ga]Ga-FAPI, though the TBRmax difference did not reach statistical significance (mean difference: 7.71, 95% CI: - 0.58-16.01). For lymph node metastasis detection, [68 Ga]Ga-FAPI outperformed [18 F]FDG with an odds ratio of 2.81 (95% CI: 1.07-7.35), and for distant metastases, the odds ratio was 3.45 (95% CI: 1.12-10.63). However, moderate variability was observed across the studies for lymph nodes and organ metastases (I2 = 46.9 and 52.4%, respectively). CONCLUSION: [68 Ga]Ga-FAPI PET/CT offers superior diagnostic performance and tumor uptake compared to [18 F]FDG PET/CT in BTCs, particularly for lymph nodes and distant metastasis detection. These findings support the potential clinical utility of [68 Ga]Ga-FAPI PET/CT as a preferred imaging modality in BTCs, though further research is needed to standardize protocols and confirm these results in larger cohorts.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Msherghi A, Abuajamieh M, Ekreer M, et al. Comparative diagnostic performance of [68 Ga]Ga-FAPI PET/CT and [18 F]FDGPET/CT in biliary tract cancers: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2025. PMID: 40214739. doi:10.1007/s00259-025-07264-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。